Type 3 Macular Neovascularization in Age-related Macular Degeneration

IF 5.7 Q1 OPHTHALMOLOGY
Riccardo Sacconi MD, PhD , Paolo Forte MD , Giulia Corradetti MD , Eliana Costanzo MD , Vittorio Capuano MD , Elodie Bousquet MD , Federico Beretta MD , Serena Iannuzzi MD , Maria Sole Polito MD , Massimo Nicolò MD , Mariacristina Parravano MD , Eric Souied MD, PhD , David Sarraf MD , SriniVas Sadda MD , Francesco Bandello MD , Giuseppe Querques MD, PhD
{"title":"Type 3 Macular Neovascularization in Age-related Macular Degeneration","authors":"Riccardo Sacconi MD, PhD ,&nbsp;Paolo Forte MD ,&nbsp;Giulia Corradetti MD ,&nbsp;Eliana Costanzo MD ,&nbsp;Vittorio Capuano MD ,&nbsp;Elodie Bousquet MD ,&nbsp;Federico Beretta MD ,&nbsp;Serena Iannuzzi MD ,&nbsp;Maria Sole Polito MD ,&nbsp;Massimo Nicolò MD ,&nbsp;Mariacristina Parravano MD ,&nbsp;Eric Souied MD, PhD ,&nbsp;David Sarraf MD ,&nbsp;SriniVas Sadda MD ,&nbsp;Francesco Bandello MD ,&nbsp;Giuseppe Querques MD, PhD","doi":"10.1016/j.oret.2024.11.011","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To identify baseline OCT predictors of the 3-year macular atrophy (MA) development for type 3 (T3) macular neovascularization (MNV) secondary to neovascular age-related macular degeneration (nAMD) treated by anti-VEGF therapy.</div></div><div><h3>Design</h3><div>Multicenter, retrospective, longitudinal study.</div></div><div><h3>Participants</h3><div>We included patients with treatment-naive T3 MNV secondary to nAMD at baseline, treated with anti-VEGF during a 3-year follow-up.</div></div><div><h3>Methods</h3><div>Patients were identified from 6 retinal referral institutions: (1) San Raffaele University, Milan, Italy; (2) University of Genova, Genova, Italy; (3) Doheny Eye Institute, Los Angeles; (4) Stein Eye Institute, Los Angeles; (5) University of Paris Est, Creteil, France; and (6) Istituto di Ricovero e Cura a Carattere Scientifico Bietti Foundation, Rome, Italy. Several baseline predictors of 3-year MA area were analyzed based on structural OCT and demographics.</div></div><div><h3>Main Outcome Measures</h3><div>Multivariate analysis to identify baseline independent predictors of the 3-year MA development for T3 MNV secondary to nAMD treated by anti-VEGF therapy.</div></div><div><h3>Results</h3><div>We included 131 eyes of 131 patients (mean age, 80 ± 6 years; 81% females). Best-corrected visual acuity was 0.49 ± 0.40 logarithm of the minimum angle of resolution (logMAR) at the baseline and significantly decreased to 0.59 ± 0.43 logMAR at the end of 3-year follow-up (<em>P</em> &lt; 0.001). Patients were treated with 11 ± 6 anti-VEGF injections and developed atrophy in 75% of cases (from 18% at the baseline). Eyes that developed 3-year MA were treated with a significantly lower number of injections compared with eyes without MA (9.9 ± 5.5 vs. 14.7 ± 7.2 injections, <em>P</em> &lt; 0.001). The most relevant independent predictors at baseline of MA area at 3-year follow-up were: area of MA at baseline (<em>P</em> &lt; 0.001), age-related macular degeneration phenotype (presence of reticular pseudodrusen) (<em>P</em> = 0.017), baseline presence of nascent geographic atrophy (<em>P</em> = 0.008), and the baseline presence of subretinal hyperreflective material (<em>P</em> = 0.002).</div></div><div><h3>Conclusions</h3><div>Macular atrophy development is a frequent complication of T3 MNV treated with anti-VEGF injections. Several factors could be considered baseline predictors of atrophy development during the anti-VEGF treatment.</div></div><div><h3>Financial Disclosure(s)</h3><div>The author(s) have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Pages 546-555"},"PeriodicalIF":5.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Retina","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468653024005414","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

To identify baseline OCT predictors of the 3-year macular atrophy (MA) development for type 3 (T3) macular neovascularization (MNV) secondary to neovascular age-related macular degeneration (nAMD) treated by anti-VEGF therapy.

Design

Multicenter, retrospective, longitudinal study.

Participants

We included patients with treatment-naive T3 MNV secondary to nAMD at baseline, treated with anti-VEGF during a 3-year follow-up.

Methods

Patients were identified from 6 retinal referral institutions: (1) San Raffaele University, Milan, Italy; (2) University of Genova, Genova, Italy; (3) Doheny Eye Institute, Los Angeles; (4) Stein Eye Institute, Los Angeles; (5) University of Paris Est, Creteil, France; and (6) Istituto di Ricovero e Cura a Carattere Scientifico Bietti Foundation, Rome, Italy. Several baseline predictors of 3-year MA area were analyzed based on structural OCT and demographics.

Main Outcome Measures

Multivariate analysis to identify baseline independent predictors of the 3-year MA development for T3 MNV secondary to nAMD treated by anti-VEGF therapy.

Results

We included 131 eyes of 131 patients (mean age, 80 ± 6 years; 81% females). Best-corrected visual acuity was 0.49 ± 0.40 logarithm of the minimum angle of resolution (logMAR) at the baseline and significantly decreased to 0.59 ± 0.43 logMAR at the end of 3-year follow-up (P < 0.001). Patients were treated with 11 ± 6 anti-VEGF injections and developed atrophy in 75% of cases (from 18% at the baseline). Eyes that developed 3-year MA were treated with a significantly lower number of injections compared with eyes without MA (9.9 ± 5.5 vs. 14.7 ± 7.2 injections, P < 0.001). The most relevant independent predictors at baseline of MA area at 3-year follow-up were: area of MA at baseline (P < 0.001), age-related macular degeneration phenotype (presence of reticular pseudodrusen) (P = 0.017), baseline presence of nascent geographic atrophy (P = 0.008), and the baseline presence of subretinal hyperreflective material (P = 0.002).

Conclusions

Macular atrophy development is a frequent complication of T3 MNV treated with anti-VEGF injections. Several factors could be considered baseline predictors of atrophy development during the anti-VEGF treatment.

Financial Disclosure(s)

The author(s) have no proprietary or commercial interest in any materials discussed in this article.
AMD 中的 3 型 MNV:3 年黄斑萎缩发展的基线预测因素。
目的:确定抗血管内皮生长因子疗法(anti-VEGF)治疗继发于新生血管性年龄相关性黄斑变性(nAMD)的3型黄斑新生血管(MNV)3年黄斑萎缩(MA)发展的基线光学相干断层扫描(OCT)预测因素:多中心、回顾性、纵向研究:我们纳入了基线时继发于 nAMD 的 3 型 MNV 患者,他们在 3 年的随访期间接受了抗血管内皮生长因子治疗:患者来自六家视网膜转诊机构:1)意大利米兰的圣拉斐尔大学;2)意大利热那亚的热那亚大学;3)美国洛杉矶的多尼眼科研究所;4)美国洛杉矶的斯坦因眼科研究所;5)法国克里特尔的东巴黎大学;6)意大利罗马的IRCCS Bietti基金会。主要结果指标:多变量分析,以确定抗血管内皮生长因子疗法治疗继发于nAMD的3型MNV患者3年MA发展的基线独立预测因素:我们纳入了 131 名患者的 131 只眼睛(平均年龄为 80±6 岁,81% 为女性)。基线最佳矫正视力为 0.49±0.40 LogMAR,3 年随访结束时显著下降至 0.59±0.43 LogMAR(p结论:黄斑萎缩是接受抗血管内皮生长因子注射治疗的3型MNV的常见并发症。在抗血管内皮生长因子治疗期间,有几种因素可被视为黄斑萎缩发展的基线预测因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Ophthalmology. Retina
Ophthalmology. Retina Medicine-Ophthalmology
CiteScore
7.80
自引率
6.70%
发文量
274
审稿时长
33 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信